EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Cancer antigen 15-3 as a key prognostic marker for breast cancer recurrence: Insights from a single center

Nora H. Trabulsi, Linah Bataweel, Hind Alsulami, Amjad Alzahrani, Alaa Shabkah, Ali Farsi, Mai Kadi, Marwan Al-Hajeili, Abdullah Al Qurashi, Salma Sait, Omar Iskandarani

Saudi Surgical Journal · 2026-01 · 14 (1) · 15-21

DOI: 10.4103/ssj.ssj_29_25 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Saudi Surgical Journal, online erschienen am 17.07.2026. Verfasst von Nora H. Trabulsi und 10 weiteren Autor:innen. Die Arbeit nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Breast cancer (BC) remains a leading cause of cancer-related mortality among women worldwide. Although numerous prognostic indicators exist, cancer antigen 15-3 (CA15-3) has garnered significant attention. Comprehensive studies from Saudi Arabia focusing on this marker are nonetheless lacking.

Objectives

To identify significant predictors of BC recurrence, with a primary focus on the role of CA15-3 as a prognostic marker in female BC patients.

Design

This was a single-center retrospective study.

Setting

King Abdulaziz University Hospital, Saudi Arabia. Patients, Materials, and Methods: Patient records of 506 female BC patients were reviewed. Among them, 121 experienced BC recurrence. Univariate and multivariate analyses were conducted to identify factors associated with tumor recurrence. Main Outcome Measures: The study assessed the role of CA15-3 and other factors as predictors of BC recurrence and prognosis. Sample Size: A total of 506 female BC patients were included in the study.

Conclusion

CA15-3 was identified as an effective predictor of BC prognosis in the studied population. Key predictors of tumor recurrence included the highest levels of CA15-3 (odds ratio [OR] = 5.72, 95% confidence interval [CI] = 3.32–9.86, P < 0.0001), advanced lymph node involvement (OR = 2.33, 95% CI = 1.22–4.47, P = 0.01), and receiving adjuvant chemotherapy (OR = 2.13, 95% CI = 1.07–4.22, P < 0.001). Regular assessment of CA15-3 in clinical practice may improve patient management and predict outcomes.

Limitations

This study was conducted at a single center with a retrospective design, and the findings are limited to the studied population. Larger studies are needed to confirm these results.

Zitieren

APA

Trabulsi, N. H., Bataweel, L., Alsulami, H., Alzahrani, A., Shabkah, A., Farsi, A., Kadi, M., Al-Hajeili, M., Qurashi, A. A., Sait, S., & Iskandarani, O. (2026). Cancer antigen 15-3 as a key prognostic marker for breast cancer recurrence: Insights from a single center. Saudi Surgical Journal, 14(1), 15-21. https://doi.org/10.4103/ssj.ssj_29_25

Vancouver

Trabulsi NH, Bataweel L, Alsulami H, Alzahrani A, Shabkah A, Farsi A, et al. Cancer antigen 15-3 as a key prognostic marker for breast cancer recurrence: Insights from a single center. Saudi Surgical Journal. 2026;14(1):15-21. doi:10.4103/ssj.ssj_29_25

BibTeX
@article{Trabulsi2026,
  author = {Trabulsi, Nora H. and Bataweel, Linah and Alsulami, Hind and Alzahrani, Amjad and Shabkah, Alaa and Farsi, Ali and Kadi, Mai and Al-Hajeili, Marwan and Qurashi, Abdullah Al and Sait, Salma and Iskandarani, Omar},
  title = {Cancer antigen 15-3 as a key prognostic marker for breast cancer recurrence: Insights from a single center},
  journal = {Saudi Surgical Journal},
  year = {2026},
  volume = {14},
  number = {1},
  pages = {15--21},
  doi = {10.4103/ssj.ssj_29_25}
}
Kostenlos starten →